HAIXI PHARMA (02637.HK): IND Application of HXP089 for Glioblastoma Approved by NMPA

NewTimeSpace · 2026/07/14 17:15 · By Boyuan Chen

NewTimeSpace News:HAIXI PHARMA(02637.HK) announced that the Investigational New Drug (IND) application for self-developed asset HXP089 to treat glioblastoma has been approved by the Center for Drug Evaluation of NMPA, authorising relevant clinical trials. It marks the Group’s third innovative candidate entering clinical development, following C019199 (oncology indication) and HXP056 (ophthalmology indication).

NewTimeSpace News: HAIXI PHARMA (02637.HK) released a voluntary announcement on 14 July 2026. The Investigational New Drug (IND) application for self-discovered HXP089 for the treatment of glioblastoma (GBM) has been granted approval by the Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA), permitting initiation of clinical studies. This is the Group’s third innovative drug to progress into clinical stage, subsequent to C019199 (oncology indication) and HXP056 (ophthalmology indication).

HXP089 is a new-generation small-molecule selective multi-target therapeutic developed on Haixi Pharma’s proprietary small-molecule discovery platform MultiSel-Opt. Precise structural optimisation enables synergistic modulation of multiple key disease pathways. The candidate exhibits favourable blood-brain barrier (BBB) penetration capacity and is expected to overcome limitations of conventional single-target agents for glioblastoma treatment.

Current standard-of-care for glioblastoma consists of surgery combined with radiotherapy and chemotherapy yet suffers from high recurrence rates. Globally, there remains a shortage of effective standard therapeutic options after disease relapse. The development of HXP089 is expected to address this unmet medical need. The latest IND approval supports clinical studies to evaluate the safety, tolerability and preliminary efficacy profile of HXP089 in target patient populations.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

HAIXI PHARMA 02637.HK IND Approval